Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts buried in 300-page reports, convertible-note details scattered across exhibits, and sudden Form 4 trades by ImmunityBio insiders—biotech disclosures aren’t light reading. If you have ever searched "ImmunityBio SEC filings explained simply" or wondered how to spot safety-signal language before the next data cut, you know the challenge.
Stock Titan solves it. Our AI parses every ImmunityBio annual report 10-K simplified, each ImmunityBio quarterly earnings report 10-Q filing, and every ImmunityBio 8-K material events explained, then delivers concise annotations. Want a quick take on cash runway or milestone payments? The platform highlights them instantly. Need real-time alerts for ImmunityBio Form 4 insider transactions real-time or to track ImmunityBio executive stock transactions Form 4 during pivotal trial phases? You’ll receive them within seconds of EDGAR posting. Our coverage spans the full spectrum—S-1 for at-the-market offerings, ImmunityBio proxy statement executive compensation details, and the hard-to-decode footnotes inside convertible debt agreements.
Whether you’re screening "ImmunityBio earnings report filing analysis" for R&D spend trends or simply trying to understand how the IL-15 superagonist Anktiva affects risk factors, our AI-powered summaries, keyword search, and side-by-side comparisons keep you ahead. Monitor ImmunityBio insider trading Form 4 transactions, review pipeline progress tucked into MD&A, and grasp material agreements without wading through legal jargon. Understanding ImmunityBio SEC documents with AI means you spend less time decoding and more time deciding.
ImmunityBio (IBRX) filed its Q3 2025 report showing rapid revenue ramp but continued losses and liquidity pressure. Total revenue reached $32.1 million for the quarter, up from $6.1 million a year ago, driven by U.S. commercialization of ANKTIVA. For the nine months, revenue was $75.0 million versus $7.2 million in 2024.
The company reported a Q3 net loss of $67.3 million and a loss from operations of $55.6 million. Year-to-date operating cash outflows were $234.6 million. Cash and cash equivalents were $60.2 million and marketable securities were $197.6 million as of September 30, 2025. Accounts receivable increased to $32.0 million, reflecting growing product sales.
Total liabilities were $1.04 billion, including a related-party convertible note at fair value of $500.8 million, a revenue interest liability of $316.1 million, and warrant liabilities of $115.2 million. The company raised $346.8 million net through equity offerings year-to-date, including “at-the-market” sales and other equity issuances. Shares outstanding were 984,965,179 as of October 30, 2025.
Management disclosed substantial doubt about continuing as a going concern without additional funding, noting reliance on existing cash, product sales, future equity offerings, and potential affiliated loans. In July 2025, ANKTIVA received UK marketing authorization, the first approval outside the U.S.
ImmunityBio, Inc. furnished a press release announcing its financial results for the third quarter and nine months ended September 30, 2025, and its financial position as of September 30, 2025.
The press release, dated November 4, 2025, is included as Exhibit 99.1 to this Form 8-K. The information under Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act.
ImmunityBio (IBRX) increased its authorized common stock to 1,650,000,000 shares from 1,350,000,000 through a stockholder written consent, approved by holders of 649,794,019 shares (approximately 66.0% of voting power). The amendment was recommended by the Board and will become effective no earlier than twenty calendar days after mailing; the company anticipates an effective date on or about November 10, 2025.
The company states the higher authorization is intended to cover current committed issuances and expected funding needs, including potential equity raises or convertible instruments that require reserved shares. As context, 984,965,179 shares were outstanding as of October 7, 2025. The filing notes that issuing additional shares could dilute existing stockholders and may affect the share price.
No appraisal or dissenters’ rights apply, and no further stockholder vote is required.
ImmunityBio, Inc. stockholders holding 649,794,019 shares, representing approximately
ImmunityBio reported a federal court's preliminary approval of a proposed settlement to resolve several stockholder derivative lawsuits brought nominally on behalf of the company. Under the Stipulation, the company will adopt specified corporate governance reforms and will pay attorneys' fees in exchange for a full and complete release and dismissal of the derivative claims. The company states it expects those attorneys' fees will be funded by its insurance carrier. The court has set a final approval hearing for November 4, 2025. The company has posted the Notice and the Stipulation to its Investor Relations website and attached them as Exhibits 99.1 and 99.2.
ImmunityBio, Inc. (IBRX) 10-Q — Quarter ended June 30, 2025: Condensed consolidated assets totaled $402,076 as of June 30, 2025, including $137,658 cash and cash equivalents, $16,000 marketable securities and $22,126 accounts receivable. Total current assets were $208,132. Major non‑current assets include PP&E net $133,004 and goodwill/intangibles net $14,977. Total liabilities were $971,895, driven notably by a $492,084 related‑party convertible note payable and a $307,049 revenue interest liability; warrant liabilities were $66,957. Stockholders' deficit was $(570,749).
Operating results and cash flows: Product revenue increased to $26,421 for Q2 2025 (Q2 2024: $990) and $42,930 for six months 2025 (six months 2024: $990). Loss from operations was $(71,285) for Q2 and $(135,714) for six months; net loss was $(92,574) for Q2 and $(222,240) for six months. Net cash used in operating activities for the six months was $(165,651). The company discloses an accumulated deficit of $3.6 billion and states substantial doubt about going concern without additional funding, though management cites expected support from the Founder and other sources.
ImmunityBio (IBRX) filed an 8-K disclosing a capital raise. On 24 Jul 2025 the company executed a Securities Purchase Agreement to sell 29,629,632 common shares together with five-year warrants for an equal number of shares. Each share-and-warrant unit is priced at $2.70, while the warrants carry a $3.24 exercise price and become immediately exercisable. Gross proceeds are expected to be about $80 million before fees and expenses; closing is targeted for 28 Jul 2025 subject to customary conditions.
Piper Sandler & Co. will act as exclusive placement agent under a separate agreement and will receive a cash fee equal to 6.0 % of gross proceeds (no fee on warrant exercises). The securities are being issued from the company’s effective shelf registration statement on Form S-3ASR.
The 8-K also references two press releases dated 25 Jul 2025: (i) a business update with preliminary, unaudited Q2 results and regulatory developments, and (ii) an announcement of the registered direct offering. Full financial figures were not included in the filing; exhibits provide the SPA, warrant form, placement agency agreement, legal opinion and related consents.
ImmunityBio has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, a large accelerated filer based in San Diego, is led by CEO Richard Adcock and Executive Chairman Patrick Soon-Shiong, who serves as Global Chief Scientific and Medical Officer.
Key aspects of the filing include:
- Registration of securities for employee benefit plan purposes
- Incorporation of recent financial documents including 2024 Annual Report and Q1 2025 quarterly report
- Comprehensive indemnification provisions for directors and officers
- Strong corporate governance structure with Cheryl L. Cohen serving as Lead Independent Director
The filing includes standard undertakings required by the SEC, including commitments to file post-effective amendments when necessary and provisions regarding indemnification. The registration is supported by legal opinion from Wilson Sonsini Goodrich & Rosati and includes required consents from independent auditors.
ImmunityBio director Christobel Selecky received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative securities transaction details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continuing service as defined in 2025 Equity Incentive Plan
This represents a standard annual director equity compensation grant. The filing was signed by Jason Liljestrom as attorney-in-fact on June 20, 2025. The options are held directly by the reporting person with no indirect beneficial ownership reported.
FAQ
What is the current stock price of Immunitybio (IBRX)?
What is the market cap of Immunitybio (IBRX)?
